Clinical Significance

CA50 is a sialic acid ester and sialic acid glycoprotein. It is a non-specific broad-spectrum tumor marker with certain cross-antigenicity with cancer antigens 19-9. It is mainly used for pancreatic cancer, colon/rectal cancer, and gastric cancer. auxiliary diagnosis. Generally not present in normal tissues, when cells become malignant, glycosylase is activated, resulting in changes in cell surface glycosyl structure and becomes a CA50 marker. Other lung cancer, liver cancer, ovarian or cervical cancer, bile duct cancer, bladder cancer, etc. all have a large percentage increase. In addition, some ulcerative colitis, liver cirrhosis, melanoma, lymphoma, autoimmune diseases, etc. can also see increased CA50.